Company Overview and News

[Press] Shale Gas Hydraulic Fracturing Market will Exhibit a Steady 9.8% CAGR through 2027

2018-04-13 oilvoice
Future Market Insights assesses the shale gas hydraulic fracturing market in the U.S, Canada, and China in its newly published report titled, “Shale Gas Hydraulic Fracturing Market: Canada, US, and China Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027.” According to the report, the US market production value is anticipated to expand from 18,059 BCF (2017) at a 9.8% CAGR, Canadian market's production volume of 213.
Upvote Downvote

'Blame It On China'

2018-04-10 seekingalpha
In the "slow growth forever" global economy, having access to China's market is imperative to improving Millennial standard of living.
Upvote Downvote

Appalachian Natural Gas Production: What’s Driving the Growth?

According to the US Energy Information Administration or EIA, drilling wells in Appalachia have become increasingly productive, owing to improved efficiencies in horizontal drilling and hydraulic fracturing in the region. These efficiencies include longer laterals, faster drilling, better targeting of wells, and advanced technology.
Upvote Downvote

EQT Corporation to Spin off Its Midstream Business

On February 21, 2018, EQT Corporation (EQT) announced its plans to spin off its midstream business, creating a standalone publicly traded corporation, which will be referred to as “NewCo.”
Upvote Downvote

Rice Midstream Partners: To Hold Or To Bail

2018-02-28 seekingalpha
When EQT announced it would acquire Rice Energy last summer, Rice Midstream Partners appeared to be abandoned.
Upvote Downvote

Why EQT Is Spinning Off Its Midstream Operations

On February 21, 2018, EQT (EQT) announced its plan to separate its midstream operations into a stand-alone entity. That could result in EQT being a pure-play upstream company with the new entity focused on midstream operations. The company expects to close the tax-free separation by the end of 3Q18. Under the separation plan, EQT shareholders will retain their EQT shares and receive pro rata shares of the new midstream company.
Upvote Downvote

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2017 Update

2018-02-22 seekingalpha
Halvorsen's 13F portfolio value increased from $15.44B to $16.26B. The number of positions remained steady at 59.
Upvote Downvote

Will EQT's Spin-Off of Midstream Businesses Prove Beneficial?

2018-02-22 zacks
EQT Corporation’s (EQT - Free Report) board of directors has finally succumbed to months of pressure from investors and agreed to separate the company's upstream and midstream businesses. It will form an independent publicly traded company (NewCo), whose operations will focus on the midstream businesses of EQT. Following the news of spin-off, the stock declined 3.1%, making the stock fall 11.1% in the last 30-day time period.
Upvote Downvote

EQT Breaks Up the Family -- Which Is Great - Bloomberg

2018-02-21 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

EQT Corporation is spinning off its midstream pipeline business

2018-02-21 cnbc
EQT Corporation, the nation's biggest natural gas producer, will spin off its pipeline business into a new publicly traded company, the Pittsburgh-based company announced on Wednesday.
Upvote Downvote

UPDATE 2-Natgas producer EQT to spin off midstream operations amid investor pressure

2018-02-21 reuters
Feb 21 (Reuters) - Oil and gas producer EQT Corp said on Wednesday it would spin off its midstream business to create a standalone publicly traded company, yielding to months of pressure from shareholders.
Upvote Downvote

Oil Producer EQT Corp To Spin Off Midstream Operations

2018-02-21 rigzone
Feb 21 (Reuters) - Oil and gas producer EQT Corp said on Wednesday that it would separate its upstream and midstream businesses, finally giving in to months of investor pressure.
Upvote Downvote

Oil producer EQT Corp to spin off midstream operations

2018-02-21 reuters
Feb 21 (Reuters) - Oil and gas producer EQT Corp said on Wednesday that it would separate its upstream and midstream businesses, finally giving in to months of investor pressure.
Upvote Downvote

Rice Merger Drives EQT’S 4Q17 and 2017 Production and Reserves

EQT’s (EQT) production volume in 4Q17 was 294.4 Bcfe (billion cubic feet equivalent). In comparison, its 4Q16 production volumes were 198 Bcfe. The 48.7% increase in 4Q17 production was likely a result of the inclusion of Rice Energy’s production volumes. EQT completed its acquisition of Rice Energy on November 13, 2017.
Upvote Downvote

EQT Reported Upbeat Fiscal 4Q17 and 2017 Revenue and Earnings

EQT (EQT) reported its 4Q17 and 2017 earnings on February 15, 2018. It reported revenue of $1.1 billion compared to analysts’ estimate of $728 million. It reported revenue of $379 million in 4Q16.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 762760106